The efficacy of trastuzumab can be influenced by factors such as the level of HER2 expression on cancer cells, the presence of other mutations or alterations in signaling pathways, and the development of resistance over time (Jørgensen, 2024). This evidence concerns the gene ERBB2 and cancer.